Bendamustine,Pomalidomide and Dexamethasone in Relapsed and/or refractory Multiple Myeloma - BASi

All India Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•>=18 years with confirmed diagnosis of MM
•ECOG PS 0-2
•Relapsed and/or refractory after >=2 lines of therapy
•Pomalidomide and Bendamustine naive, received prior lenalidomide and determined to be refractory.
•Measurable disease as determined by one or more of following:
•Serum M protein >=0.5gm/dl
•Urine Bence Jones protein >200mg in 24 h
•In patients with light chain myeloma serum immunoglobulin free light chain >=10mg/dl or abnormal ratio as per IMWG criteria
•Adequate bone marrow function as defined by: Hb>=8g/dl, ANC>=1000/mm3 and platelets>=75,000/mm3
•Adequate LFT: T. bil <=2 times ULN, AST/ALT <=3 ULN
•Creatinine clearance <=45 ml/minute
•Written informed consent
•No contraindication to take Aspirin 75mg/d or if history of prior thrombosis, should agree to take warfarin/ LMWH.
•Participants of child bearing age should agree to use adequate contraceptives, avoid breast feeding, avoid donating sperm 28days before starting, during therapy and 28 days after end of therapy

•Peripheral neuropathy >=grade 2
•COPD with FEV1 <50% of predicted
•Congestive heart failure, myocardial infarction within 12 months prior to starting, unstable angina, poorly controlled angina.
•Allergy to compounds of similar biochemical composition to Bendamustine and pomalidomide
•Pregnant and lactating females
•PLHIV, hepatitis B and/or hepatitis C positive
•Active infection requiring systemic antibiotics/antivirals/antifungal within two weeks prior to enrolment
•Other malignancy within 2 years of enrolment
•Primary refractory multiple myeloma.

发起方